IMMUNITYBIO INC (IBRX)
US45256X1037 - Common Stock
We assign a fundamental rating of 2 out of 10 to IBRX. IBRX was compared to 587 industry peers in the Biotechnology industry. IBRX has a bad profitability rating. Also its financial health evaluation is rather negative. IBRX shows excellent growth, but is valued quite expensive already.
1. Profitability
1.1 Basic Checks
In the past year IBRX has reported negative net income.
IBRX had a negative operating cash flow in the past year.
In the past 5 years IBRX always reported negative net income.
IBRX had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
The Return On Assets of IBRX (-115.61%) is worse than 82.56% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -115.61% | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)-101.5%
ROA(5y)-102.99%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for IBRX so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
IBRX does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, IBRX has more shares outstanding
The number of shares outstanding for IBRX has been increased compared to 5 years ago.
IBRX has a better debt/assets ratio than last year.
2.2 Solvency
IBRX has an Altman-Z score of -7.15. This is a bad value and indicates that IBRX is not financially healthy and even has some risk of bankruptcy.
IBRX's Altman-Z score of -7.15 is on the low side compared to the rest of the industry. IBRX is outperformed by 70.94% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Altman-Z | -7.15 |
ROIC/WACCN/A
WACC8.9%
2.3 Liquidity
IBRX has a Current Ratio of 5.05. This indicates that IBRX is financially healthy and has no problem in meeting its short term obligations.
IBRX has a Current ratio (5.05) which is in line with its industry peers.
IBRX has a Quick Ratio of 5.05. This indicates that IBRX is financially healthy and has no problem in meeting its short term obligations.
IBRX's Quick ratio of 5.05 is in line compared to the rest of the industry. IBRX outperforms 55.38% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 5.05 | ||
| Quick Ratio | 5.05 |
3. Growth
3.1 Past
IBRX shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by 0.00%.
IBRX shows a strong growth in Revenue. In the last year, the Revenue has grown by 159.17%.
IBRX shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 65.56% yearly.
EPS 1Y (TTM)0%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q25.93%
Revenue 1Y (TTM)159.17%
Revenue growth 3Y0.65%
Revenue growth 5Y65.56%
Revenue growth Q2Q-88.89%
3.2 Future
Based on estimates for the next years, IBRX will show a quite strong growth in Earnings Per Share. The EPS will grow by 19.19% on average per year.
IBRX is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 629.94% yearly.
EPS Next Y38.62%
EPS Next 2Y26.25%
EPS Next 3Y19.19%
EPS Next 5YN/A
Revenue Next Year1805.59%
Revenue Next 2Y1191.1%
Revenue Next 3Y629.94%
Revenue Next 5YN/A
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for IBRX. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for IBRX. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as IBRX's earnings are expected to grow with 19.19% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y26.25%
EPS Next 3Y19.19%
5. Dividend
5.1 Amount
IBRX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
IMMUNITYBIO INC
NASDAQ:IBRX (5/17/2024, 7:05:14 PM)
After market: 7.68 +0.03 (+0.39%)7.65
-0.1 (-1.29%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap5.16B
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -115.61% | ||
| ROE | N/A | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 5.05 | ||
| Quick Ratio | 5.05 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)0%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y38.62%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)159.17%
Revenue growth 3Y0.65%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y